Get the Stockscreener App
2.09
18.99%
-0.49
After Hours:
2.27
0.18
+8.61%
Cyclerion Therapeutics Inc stock is traded at $2.09, with a volume of 448.53K.
It is down -18.99% in the last 24 hours and down -16.40% over the past month.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
See More
Previous Close:
$2.58
Open:
$2.26
24h Volume:
448.53K
Relative Volume:
2.21
Market Cap:
$6.01M
Revenue:
$556.00K
Net Income/Loss:
$149.00K
P/E Ratio:
-0.1201
EPS:
-17.4
Net Cash Flow:
$-16.90M
1W Performance:
-18.68%
1M Performance:
-16.40%
6M Performance:
-26.67%
1Y Performance:
-0.95%
1-Day Range:
$2.00
$2.53
1-Week Range:
$1.71
$3.00
52-Week Range:
$1.71
$5.25
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
Name
Cyclerion Therapeutics Inc
Sector
Industry
Phone
617-621-7722
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare CYCN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CYCN | 2.09 | 6.01M | 556.00K | 149.00K | -16.90M | -17.40 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-21 | Initiated | Truist | Buy |
| Sep-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-03-19 | Initiated | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc Stock (CYCN) Latest News
Cyclerion Therapeutics Inc (CYCN) Quarterly 10-Q Report - Quartzy
Cyclerion Therapeutics stock hits 52-week low at $1.75 By Investing.com - Investing.com South Africa
Cyclerion Therapeutics stock hits 52-week low at $1.75 - Investing.com India
Where Are They Now? Ironwood Pharmaceuticals - Life Science Leader Magazine
Vascular Dementia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Charsire Biotech Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP - Barchart
cyclerion therapeutics, inc. Earnings dates - RTTNews
Cyclerion Therapeutics (NASDAQ:CYCN) Trading Down 8.1% - Defense World
Analyzing Cyclerion Therapeutics (NASDAQ:CYCN) and Seelos Therapeutics (NASDAQ:SEEL) - Defense World
Cyclerion appoints Regina Graul as CEO and President - Investing.com
Cyclerion Therapeutics Promotes Regina Graul, Ph.D., to Chief Executive Officer - citybiz
Regina Graul, Ph.D., Promoted to Chief Executive Officer - StreetInsider.com
Short Interest in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Expands By 10.9% - Defense World
Cyclerion Therapeutics - BioSpace
Head-To-Head Analysis: Genelux (NASDAQ:GNLX) and Cyclerion Therapeutics (NASDAQ:CYCN) - Defense World
Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday - Quantisnow
12 Health Care Stocks Moving In Thursday's Intraday SessionAethlon Medical (NASDAQ:AEMD), Biomea Fusion ... - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday SessionAutonomix Medical (NASDAQ:AMIX), Avinger ... - Benzinga
Cyclerion Therapeutics (NASDAQ:CYCN) Trading Down 10.2% - Defense World
Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates - Yahoo Movies UK
How Much Did Cyclerion Therapeutics'(NASDAQ:CYCN) Shareholders Earn From Share Price Movements Over The ... - Yahoo New Zealand News
12 Best Biotech Penny Stocks to Invest In - Insider Monkey
Cyclerion Appoints Regina Graul, Ph.D., as President - citybiz
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator - GlobeNewswire
Cyclerion Therapeutics' Market Cap Drops To US$5.0m Leaving Insiders With Losses - Yahoo Finance
Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer - Marketscreener.com
Cyclerion in Talks on Buyout Proposal for Drug Assets; CEO Offers to Make Equity Investment - Marketscreener.com
Rapport Therapeutics Appoints Chief Operating Officer and Scientific Advisory Board Member - Business Wire
Tisento Therapeutics Raises $81M in Series A Funding - FinSMEs
Bio Startup Tisento Launches With $81M and a Brain-Penetrating Drug in the Clinic - MedCity News
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Cyclerion Announces Reverse Stock Split - Yahoo Finance
A struggling biotech wraps its main assets into a new drug company - BioPharma Dive
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018 - GlobeNewswire
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement - GlobeNewswire
Lucy Therapeutics Appoints Neuroscience Drug Discovery and Development Expert Christopher J. Winrow, Ph.D., as Chief Scientific Officer - Business Wire
BioMarin, Cyclerion Slash Workforce in the Name of Strategic Focus - BioSpace
Nasdaq Edges Higher; AngioDynamics Shares Plummet | Markets Insider - Markets Insider
Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Invest In Growth? - Yahoo Finance
Form 8-K Cyclerion Therapeutics, For: Jun 10 - StreetInsider.com
Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results - Yahoo Finance
David Greenspan's Slate Path Capital is Buying Coinbase, Stitch Fix, and More - Insider Monkey
Meme Penny Stocks Are Here to Stay; 3 For Your Summer Watchlist - Penny Stocks
Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat - GlobeNewswire
Hedge Fund and Insider Trading News: Dan Kamensky, Tiger Global Management, Bridgewater Associates, Standard General, Archegos Capital Management, Cyclerion Therapeutics Inc (CYCN), Sayona Mining Ltd (DMNXF), and More - Insider Monkey
Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress - GlobeNewswire
Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors - citybiz
Cyclerion Therapeutics Announces Departure of Chief Medical Officer - GlobeNewswire
IXICO selected by Cyclerion for new Alzheimer's disease study - PR Newswire
Cyclerion Therapeutics (NASDAQ:CYCN) Stock Quotes, Forecast and News Summary - Benzinga
Cyclerion Therapeutics Inc (NASDAQ:CYCN) Publishes The Results Of Its IW-6463 Phase 1 Transitional Pharmacology Study - BP Journal
Cyclerion Suspends Development of Olinciguat for Sickle Cell Disease - Sickle Cell Disease News
Cyclerion Therapeutics Inc Stock (CYCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):